Who are Biogen Inc.'s main suppliers?

Biogen Inc. (BIIB) key suppliers include: GENENTECH, EISAI, PURCHASER, United Community Banks, Inc., United Community Banks, Inc.. View the full supplier network at chainsifter.com/chain/BIIB.

Who are Biogen Inc.'s major customers?

Biogen Inc. (BIIB) key customers include: APELLIS, SAMSUNG-BIOEPIS, SUPERNUS-PHARMACEUTICALS-INC. View the full customer network at chainsifter.com/chain/BIIB.

What sector is Biogen Inc. in?

Biogen Inc. (BIIB) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

BIIB Supply Chain: Biogen Inc. Supplier List & 10 Relationships

5Suppliers

3Customers

2Debt Items

19Related Chains

Biogen Inc. Suppliers

Ticker	Name	Confidence	Evidence
GENENTECH	GENENTECH	92%	Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN as well as all development and commercialization activities
EISAI	EISAI	90%	We currently have a supply agreement with Eisai to manufacture LEQEMBI drug substance and drug product through the end of 2031
PURCHASER	PURCHASER	90%	the Purchaser Board has recommended that the sole stockholder of Purchaser approve and adopt the Merger
UCB	United Community Banks, Inc.	80%	A summary of development expense related to the UCB collaboration agreement is as follows
UCB	United Community Banks, Inc.	80%	Reciprocal relationship from UCB graph: Reciprocal relationship from BIIB graph: A summary of development expense related to the UCB collaboration agreement is as follows

Biogen Inc. Customers

Ticker	Name	Confidence	Evidence
APELLIS	APELLIS	92%	The Merger Agreement and the CVR Agreement and to consummate the Offer, the Merger and the other transactions contemplated by the Merger Agreement and the CVR Agreement, upon the terms and subject to…
SAMSUNG-BIOEPIS	SAMSUNG-BIOEPIS	85%	In exchange, we receive single-digit royalties on biosimilar products developed and commercialized by Samsung Bioepis
SUPERNUS-PHARMACEUTICALS-INC	SUPERNUS-PHARMACEUTICALS-INC	85%	We share 50.0 % of the net collaboration results in the U.S. with Supernus, which are recognized in collaboration profit sharing/(loss reimbursement)

Biogen Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
BIIB-DEBT-8194	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2008-12-31.
BIIB-DEBT	Debt stack $6.6B	90%	Market cache reports total debt of $6.6B.

Biogen Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Biogen Inc..

Biogen Inc. Ownership

Holder	Name	Confidence	Evidence
BIIB-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC	VANGUARD CAPITAL MANAGEMENT LLC	90%	13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 1007 tracked holders.

Biogen Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
COLL	Collegium Pharmaceutical, Inc.	100.00	2
ZVRA	Zevra Therapeutics, Inc.	100.00	2
SGIOF	Shionogi & Co., Ltd.	100.00	2
UCB	United Community Banks, Inc.	100.00	1	['supplier']
ORANY	ORANGE	50.00	2
TKPHF	Takeda Pharmaceutical Company Limited	50.00	2
LCTX	Lineage Cell Therapeutics, Inc.	50.00	2
XENE	Xenon Pharmaceuticals Inc.	50.00	2
ZAMBON	ZAMBON	50.00	2
CLOVER	CLOVER	50.00	2
UCPS	UCPS	50.00	2
APLS	Apellis Pharmaceuticals, Inc.	38.88	1	['receiving']
SUPN	Supernus Pharmaceuticals, Inc.	38.88	1	['receiving']
BIOGEN	BIOGEN	24.13	2
CAH	Cardinal Health, Inc.	15.81	2
MCK	McKesson Corporation	15.81	2
UTHR	United Therapeutics Corporation	14.78	2
TMO	Thermo Fisher Scientific Inc.	14.78	2
RAPP	Rapport Therapeutics, Inc.	14.78	2

Biogen Inc. Supply Chain